These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 36442773)
21. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo. Jia C; Kong D; Guo Y; Li L; Quan L Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410 [TBL] [Abstract][Full Text] [Related]
22. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma. Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537 [TBL] [Abstract][Full Text] [Related]
23. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma. Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013 [TBL] [Abstract][Full Text] [Related]
24. ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance. Caillot M; Zylbersztejn F; Maitre E; Bourgeais J; Hérault O; Sola B Cells; 2020 Oct; 9(11):. PubMed ID: 33114738 [TBL] [Abstract][Full Text] [Related]
25. A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling. Gao J; Zhou J; Zhang M; Zhang Y; Zeng Y; Li S; Xu K; Yao R Mol Cell Biochem; 2024 Apr; 479(4):843-857. PubMed ID: 37204666 [TBL] [Abstract][Full Text] [Related]
26. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma. Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827 [TBL] [Abstract][Full Text] [Related]
27. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts. Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768 [TBL] [Abstract][Full Text] [Related]
28. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668 [TBL] [Abstract][Full Text] [Related]
29. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma. Gu Z; Wang X; Cheng R; Cheng L; Zhong Z Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956 [TBL] [Abstract][Full Text] [Related]
30. Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma. Wu X; Xia J; Zhang J; Zhu Y; Wu Y; Guo J; Chen S; Lei Q; Meng B; Kuang C; Feng X; He Y; Shen Y; Li X; Qiu L; Li G; Zhou W Br J Haematol; 2020 Jul; 190(1):52-66. PubMed ID: 32037523 [TBL] [Abstract][Full Text] [Related]
31. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma. Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance. Kim A; Seong KM; Kang HJ; Park S; Lee SS Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678 [TBL] [Abstract][Full Text] [Related]
33. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312 [TBL] [Abstract][Full Text] [Related]
34. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma. Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584 [TBL] [Abstract][Full Text] [Related]
35. Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma. Salem K; McCormick ML; Wendlandt E; Zhan F; Goel A Redox Biol; 2015; 4():23-33. PubMed ID: 25485927 [TBL] [Abstract][Full Text] [Related]
36. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms]. Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400 [No Abstract] [Full Text] [Related]
37. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273 [TBL] [Abstract][Full Text] [Related]
38. Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells. Yao Y; Sun Y; Shi M; Xia D; Zhao K; Zeng L; Yao R; Zhang Y; Li Z; Niu M; Xu K Oncotarget; 2016 Nov; 7(45):73497-73508. PubMed ID: 27634873 [TBL] [Abstract][Full Text] [Related]
39. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib. Malek E; Driscoll JJ Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530 [TBL] [Abstract][Full Text] [Related]
40. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib. Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]